Thursday, 26 July 2001

ASX RELEASE

Novogen Research & Development Review

This edition of the Novogen newsletter is a review of the Company’s research and development activities. The substantial growth in this area of the Company’s activity over the past 2 years is highlighted by the large number of clinical studies being conducted globally, the increasing amount of data being generated by those studies, an expanding product pipeline, and an expanding patent portfolio.

All of this effort continues to grow the intrinsic value of the Company’s greatest financial asset – its intellectual property. This newsletter is intended to give shareholders an insight into the Company’s intellectual property position so that they might better understand the growing value of that asset.

Copyright © 2001 - Marshall Edwards Inc.